Avalo Therapeutics Inc. [NASDAQ: AVTX] traded at a low on 09/08/23, posting a -1.90 loss after which it closed the day’ session at $0.09. The company report on September 6, 2023 at 7:00 AM that Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference.
The pre-recorded presentation will be made available on Monday, September 11, 2023 at 7:00 AM ET. A webcast of the pre-recorded presentation can be accessed under the “News/Events” page in the Investors section of the Company’s website at www.avalotx.com.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The results of the trading session contributed to over 26998458 shares changing hands. Over the past one week, the price volatility of Avalo Therapeutics Inc. stands at 13.97% while the volatility over the past one month is 17.03%.
The market cap for AVTX stock reached $1.90 million, with 20.25 million shares outstanding and 20.00 million shares in the current float. Compared to the average trading volume of 5.70M shares, AVTX reached a trading volume of 26998458 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Avalo Therapeutics Inc. [AVTX]?
RBC Capital Mkts have made an estimate for Avalo Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 24, 2021.
The Average True Range (ATR) for Avalo Therapeutics Inc. is set at 0.03, with the Price to Sales ratio for AVTX stock in the period of the last 12 months amounting to 0.11.
How has AVTX stock performed recently?
Avalo Therapeutics Inc. [AVTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.00. With this latest performance, AVTX shares dropped by -39.02% in over the last four-week period, additionally sinking by -96.16% over the last 6 months – not to mention a drop of -98.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVTX stock in for the last two-week period is set at 28.37, with the RSI for the last a single of trading hit 29.94, and the three-weeks RSI is set at 30.91 for Avalo Therapeutics Inc. [AVTX]. The present Moving Average for the last 50 days of trading for this stock 0.2069, while it was recorded at 0.0944 for the last single week of trading, and 2.6859 for the last 200 days.
Avalo Therapeutics Inc. [AVTX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Avalo Therapeutics Inc. [AVTX] shares currently have an operating margin of -207.41 and a Gross Margin at +80.77. Avalo Therapeutics Inc.’s Net Margin is presently recorded at -230.78.
Return on Total Capital for AVTX is now -102.35, given the latest momentum, and Return on Invested Capital for the company is -125.83. Return on Equity for this stock declined to -684.77, with Return on Assets sitting at -73.35. Additionally, AVTX Total Debt to Total Capital is recorded at 185.65, with Total Debt to Total Assets ending up at 70.91.
Reflecting on the efficiency of the workforce at the company, Avalo Therapeutics Inc. [AVTX] managed to generate an average of -$2,082,900 per employee. Receivables Turnover for the company is 5.37 with a Total Asset Turnover recorded at a value of 0.32.Avalo Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.30.
Insider trade positions for Avalo Therapeutics Inc. [AVTX]
The top three institutional holders of AVTX stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in AVTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in AVTX stock with ownership which is approximately 5.7381%.
